Wyniki wyszukiwania:

This issue of Hematology/Oncology Clinics is focused on Hodgkin's Lymphoma and covers such topics as First HRS-cell line L428 and the detection of the CD-30 Antigen, "Normal" CD30-B-lymphocytes, CD-30-Antigen, Combination-Chemo-Radiotherapy, Early intensification (escBEACOPP), Customized/Targeted Therapy, and more.

Lisa hat seit Wochen Nachtschweiß und Juckreiz und spürt am Hals einen Knoten. Sie geht zu einem Arzt, der Lymphdrüsenkrebs diagnostiziert - »Morbus Hodgkin«. Ihre Welt bricht zusammen. Sie hat gerade das Jurastudium begonnen, ist von zu Hause ausgezogen und zum ersten Mal richtig verliebt. Und nun Krebs. Das Ende ihrer Lebenspläne?2500 Menschen erkranken jährlich in Deutschland an »Morbus Hodgkin«. In den 1980er-Jahren verlief die Erkrankung in den meisten Fällen tödlich, doch heute können über 95 Prozent der Patienten und Patientinnen geheilt werden. Dazu hat die Forschung von...

In the field of Hodgkin's lymphoma, many new data have been collected during the last decade both on the cell of origin of this disease and on more effective therapies to cure the majority of pa- tients even in the advanced stages. Therefore, it seems to be justi- fied to compile these new data in a special volume of Recent Re- sults in Cancer Research. This volume summarizes the contribu- tions presented at the First International Symposium on Hodgkin's Disease that took place in Cologne (FRG) on October 2-3, 1988. There is little doubt that the Hodgkin and Reed-Sternberg (H and RS) cells...

Malignancies originating from the urogenital tract account for about 20% of all solid neoplasias. The various tumor types, including carcinoma of the prostate, transitional cell carcinoma, renal cell carcinoma, and testicular germ cell tumors, differ widely in terms of biological features, in- cidence and appearance, diagnostic work-up and manage- ment. It is not surprising that this complexity of urologic oncology with its related problems has increasingly attracted both experimental investigators and clinical experts. Only time will tell whether the achievements that today are con- sidered-...